Summary
Bristol Myers Squibb (BMY) filed its 10-Q for the period ending June 29, 2019, reporting on its financial performance and operational highlights. The filing indicates continued focus on its core pharmaceutical business, with investments in research and development driving innovation and pipeline expansion. Investors should pay close attention to the company's revenue streams, particularly the performance of key products, and its strategic initiatives aimed at long-term growth and market leadership in the biopharmaceutical sector. The report also details the company's financial position, liquidity, and any significant legal or regulatory matters that could impact future results.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $6.27B |
| Cost of Revenue | $1.97B |
| Gross Profit | $4.30B |
| R&D Expenses | $1.32B |
| SG&A Expenses | $1.08B |
| Operating Expenses | $4.50B |
| Interest Expense | $123.00M |
| Net Income | $1.43B |
| EPS (Basic) | $0.88 |
| EPS (Diluted) | $0.87 |
| Shares Outstanding (Basic) | 1.64B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1The report covers the financial performance for the quarter ended June 29, 2019, providing an update on BMY's operational and financial standing.
- 2Key financial statements including Consolidated Statements of Earnings, Comprehensive Income, Balance Sheets, and Cash Flows are presented.
- 3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition, results of operations, and market risk.
- 4The filing includes disclosures on legal proceedings and risk factors, which are crucial for understanding potential challenges and uncertainties.
- 5Information regarding unregistered sales of equity securities and the use of proceeds, if any, is also provided.
- 6Exhibits are listed, which may contain important supporting documentation for the financial data and operational details.
Frequently Asked Questions
This 10-Q filing provides a quarterly update on Bristol Myers Squibb's financial performance, operational results, and financial condition for the period ending June 29, 2019. It includes detailed financial statements, management's discussion of results, and disclosures on risk factors and legal proceedings.
Information regarding BMY's revenue and profitability can be found in the 'Consolidated Statements of Earnings and Comprehensive Income' and within the 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' sections of the filing.
The filing includes a section on 'Risk Factors' (Item 1A) which details potential challenges and uncertainties the company faces. 'Legal Proceedings' (Item 1) outlines any significant ongoing legal matters that could impact the company's financial or operational standing.
Yes, the 'Consolidated Statements of Cash Flows' provides details on the company's cash generation and usage, while the 'Consolidated Balance Sheets' and the MD&A section offer insights into the company's liquidity and overall financial health.